Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s share price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$11.29 and traded as high as C$11.74. Fennec Pharmaceuticals shares last traded at C$11.74, with a volume of 320 shares traded.
Fennec Pharmaceuticals Stock Down 2.1%
The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The firm's 50-day moving average price is C$11.29 and its 200-day moving average price is C$9.60. The company has a market cap of C$226.40 million, a price-to-earnings ratio of -198.87 and a beta of 0.25.
Insider Activity at Fennec Pharmaceuticals
In related news, Director Rostislav Christov Raykov sold 10,000 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of C$11.71, for a total transaction of C$117,096.00. Also, Director Jeffrey Hackman bought 15,000 shares of the stock in a transaction dated Monday, May 19th. The shares were bought at an average cost of C$9.77 per share, with a total value of C$146,580.00. In the last three months, insiders sold 39,913 shares of company stock valued at $402,086. Corporate insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
